Jianhong Wang
About Jianhong Wang
Jianhong Wang is the Head of DPMK with over 20 years of experience in clinical pharmacology and drug metabolism, known for leading the development of Biktarvy®, a top-selling HIV treatment.
Professional Title: Head of DPMK
Jianhong Wang currently holds the position of Head of Drug Metabolism and Pharmacokinetics (DPMK). In this role, Wang oversees the department's scientific and strategic direction, ensuring successful outcomes in drug metabolism and pharmacokinetic studies. This key leadership position involves working with various cross-functional teams to drive drug discovery and development initiatives.
Extensive Experience in Drug Discovery
With over 20 years of experience in the field, Jianhong Wang has made significant contributions to the discovery of multiple clinical candidates. Wang's extensive expertise in clinical pharmacology and drug metabolism has been pivotal in moving several compounds from the initial discovery phase to clinical development. Their seasoned perspective and strategic input have been critical to the success of many drug discovery projects.
Leadership in Cross-Functional Teams
Jianhong Wang has a proven track record of leading cross-functional discovery teams. In their career, Wang has effectively coordinated efforts across different departments, combining knowledge and expertise to drive project success. The ability to lead diverse groups towards a common goal has been instrumental in the development and progression of several clinical candidates.
Former Executive Director at Cortexyme
Before their current role, Jianhong Wang served as the Executive Director of Clinical Pharmacology and DMPK at Cortexyme. During this tenure, Wang was responsible for guiding the clinical pharmacology strategies and the DMPK efforts of the organization. This leadership role involved steering the scientific research direction and ensuring the successful progression of clinical pharmacology projects.
Key Contributions to Biktarvy® Development
Jianhong Wang played a crucial role in the completion of the nonclinical IND and NDA package for Biktarvy®, a best-selling HIV treatment. Leading the nonclinical team, Wang's efforts were integral to the successful regulatory approval of this pivotal medicine. Biktarvy®'s commercial success is a testament to the significant impact of Wang’s contributions.
Educational Background: PhD in Analytical Chemistry
Jianhong Wang holds a PhD in Analytical Chemistry from Iowa State University. This advanced education provided a strong foundation in analytical techniques and scientific research methodologies, which have been applied throughout Wang’s career in clinical pharmacology and drug metabolism. The rigorous training received during the PhD program has contributed to Wang's expertise and leadership in the field.